and dropping 16% for its worst day since May of 2021. The company discontinuing development of its drug to treat a type of chronic sanitis after it failed to meet primary and secondary end points in trial. That drug had been cleared by the FDA to treat a serious chronic lung disease in August of this year.Even with today's move in shares are up 141% year to date. It's still among the most valuable biotech stocks with a market cap of more than $ 35 billion. For more, Missouo healthcare strategist Jared Holes ...

Tech is back in the leadership position today. Big tech, but small caps lately have been the ones putting up some big gains. The Russell 2000 outperforming the Mag 7 over the past month, and my next next guest thinks that'll continue.Says the trade has legs next year, but expects the leadership to change. Julie Beal is chief market strategist at Kane Anderson RDN. Julie, welcome.And what do you think is about to take place. Well, I think that what's going to really start to happen is people are going to rec ...

Core Viewpoint - Capricor Therapeutics, Inc. is facing significant challenges, with its valuation disconnected from fundamentals and reliance on a single, controversial therapy, Deramiocel (CAP-1002), which has not yet generated meaningful revenue [2][3][5] Company Overview - Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other unmet medical needs in the U.S. [2] - The company has a market cap of approximately $300 million, reflecting market hope rather than solid evidence [3] Financial Performance - Capricor has been chronically unprofitable and has relied on repeated capital raises and marketing narratives to sustain operations [2] - The company's stock was trading at $26.55 as of December 15th [1] Regulatory Environment - The FDA issued a Complete Response Letter (CRL) earlier this year, indicating regulatory fragility for Deramiocel [3] - The recent HOPE-3 trial results, while meeting primary and key secondary endpoints, do not significantly alter the regulatory outlook [3][5] Clinical Data and Efficacy - Statistical significance in the HOPE-3 trial was achieved by narrow margins, indicating fragility in the data [4] - Efficacy claims are primarily based on percentage slowing of progression in a late-stage, non-ambulatory patient population, which presents inherent measurement noise [4] Market Sentiment and Future Outlook - The approval probability from the FDA remains uncertain, with the HOPE-3 results improving sentiment but not fundamentally de-risking the asset [5] - The underlying business model's dependence on speculative clinical outcomes and marginal trial data suggests prolonged regulatory friction and a potential reset closer to cash value [5]

Company Overview - Kalaris Therapeutics, Inc. (KLRS) plans to raise $50 million through a private placement by selling approximately 4.2 million shares at a price of $10 each [1] - The private placement will also include pre-funded warrants for an additional 800,000 shares [1] Investment Focus - The company is focused on identifying promising biotechnology firms that are innovating through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The approach emphasizes evaluating the scientific basis of drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

Market Performance - U.S. stocks experienced an upward trend, with the Nasdaq Composite gaining over 200 points on Thursday [1] - The Dow increased by 0.44% to 48,097.08, while the NASDAQ rose by 1.08% to 22,938.56, and the S&P 500 climbed 0.76% to 6,772.76 [1] Sector Performance - Consumer discretionary shares rose by 2% on Thursday, indicating strong performance in that sector [1] - Conversely, energy stocks fell by 0.5% during the same trading session [1] Inflation and Economic Indicators - U.S. inflation showed a greater-than-expected decline in November, with the Consumer Price Index rising by 2.7% year over year, down from 3% in September and below the expected 3.1% [2] - The Philadelphia Fed Manufacturing Index dropped by 8.5 points to -10.2 in December, missing market estimates [10] - Initial jobless claims decreased by 13,000 to 224,000 for the week ending December 13 [10] Commodity Prices - Oil prices increased by 1% to $56.47, while gold prices decreased by 0.2% to $4,365.60 [5] - Silver prices fell by 1.9% to $65.640, while copper prices rose by 0.1% to $5.4360 [5] Company-Specific Movements - Athira Pharma Inc shares surged by 84% to $7.62 following an agreement to acquire rights for lasofoxifene [8] - Trump Media & Technology Group Corp shares rose by 29% to $13.47 after signing a merger agreement with TAE Technologies [8] - FuelCell Energy Inc shares increased by 32% to $10.47 after reporting better-than-expected fourth-quarter results [8] - Insmed Inc shares dropped by 16% to $166.17 after failing to meet efficacy endpoints in a clinical study [8] - Pyxis Oncology Inc shares fell by 55% to $1.52 following preliminary data from clinical studies [8] - Actelis Networks Inc shares decreased by 47% to $0.59 after announcing a public offering [8] International Market Performance - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.56% and Spain's IBEX 35 Index rising by 0.60% [6] - Asian markets closed mixed, with Japan's Nikkei falling by 1.03% and Hong Kong's Hang Seng gaining 0.12% [9]

Group 1 - Recursion Pharmaceuticals, Inc. (RXRX) is identified as a TechBio company experiencing a rise in share price, increasing from approximately $4.5 in early October [1] - The article highlights the importance of staying updated on stocks within the biotech, pharma, and healthcare industries, emphasizing key trends and catalysts that drive valuations [1] - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, provides insights and forecasts for over 1,000 companies in the sector [1]

Core Insights - Recursion Pharmaceuticals, Inc. (RXRX) has seen a rise in share price, increasing from approximately $4.5 in early October, indicating positive market sentiment towards the company [1]. Company Overview - Recursion Pharmaceuticals is categorized as a TechBio company, focusing on biotechnology and healthcare sectors [1]. - The company is under the coverage of a biotech consultant with over five years of experience in the industry, who has analyzed more than 1,000 companies [1]. Investment Group Insights - The Haggerston BioHealth investing group provides resources for both novice and experienced biotech investors, including catalysts to monitor, buy and sell ratings, and detailed financial forecasts for major pharmaceutical companies [1]. - The group also offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis, which are essential for informed investment decisions in the biotech sector [1].

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Core Viewpoint - A class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly misleading investors regarding the efficacy of its lead product candidate, nimacimab, during the specified Class Period [1][3]. Company Overview - Skye Bioscience, Inc. is a clinical-stage biotechnology company based in San Diego, focusing on developing treatments for obesity and metabolic diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who acquired Skye securities from November 4, 2024, to October 3, 2025, and they have until January 16, 2026, to seek appointment as lead plaintiff [2]. - The complaint claims that Skye failed to disclose that the efficacy of nimacimab was lower than represented, leading to an overstatement of the drug's clinical and commercial potential [3]. Stock Performance Impact - Following the announcement on October 6, 2025, that the primary endpoint of the Phase 2a study of nimacimab was not met, Skye's stock price fell by $2.85 per share, a decline of 60%, closing at $1.90 [4].

Group 1 - Medline Inc. has recently completed a record-setting IPO, raising $6.26 billion by selling over 216 million shares, with approximately 50% of the shares allocated to top investors [1] Group 2 - The company operates in the biotechnology sector, focusing on innovative drug development and therapeutic research, leveraging scientific expertise to identify promising biotechnology companies [1]